Results 41 to 50 of about 20,698 (251)

Gut microbiota mediates semaglutide attenuation of diabetes-associated cognitive decline

Neurotherapeutics
Diabetes-associated cognitive decline (DACD), characterized by cognitive impairment, is a serious complication of diabetes mellitus (DM). Research has shown that semaglutide, a novel glucagon-like peptide-1 receptor agonist, has neurotrophic and ...
Liqin Qi, Huimin Kang, Feihui Zeng, Menglan Zhan, Cuihua Huang, Qintao Huang, Lijing Lin, Guanlian He, Xiaoying Liu, Xiaohong Liu, Libin Liu   +10 more
doaj   +1 more source

Self‐Assembling Peptide‐Adjuvant Conjugate (SaPAC) Platform for Precision Cancer Immunotherapy

Advanced Science, EarlyView.
A self‐assembling peptide–adjuvant conjugate links neoantigens to TLR7 agonism, forming cationic nanoparticles that enhance lymph‐node retention, dendritic‐cell activation, and antitumor T‐cell immunity. This chemically defined platform shows how synchronized antigen and innate stimulation can be adapted across melanoma, bladder cancer, and triple ...
Yang‐Fan Wu, Jing‐Chu Hu, Ye‐Fan Hu, Wen‐Jun Li, Li Rong, Ren‐Hao Li, Yuan Yao, Lehan Hu, Xiao‐Lei Wang, Bao‐Zhong Zhang, Yicheng Lu, Shing‐Fung Chow, Canhui Su, Thomas Yau, Clive Yik‐Sham Chung, Jian‐Dong Huang   +15 more
wiley   +1 more source

Differences between therapeutic mechanisms of resmetirom and semaglutide against MASH in western diet-fed MC4R-knockout mice

Scientific Reports
Metabolic dysfunction-associated steatotic liver disease (MASLD) can progress to steatohepatitis (MASH), which is closely associated with obesity and insulin resistance. Resmetirom, and semaglutide, have been shown to have therapeutic effects in clinical
Takumi Sugawara, Kosuke Hitaka, Mitsuharu Matsumoto, Sayuri Nakamura, Ryosuke Kobayashi, Hitoshi Kandori, Yasunori Nio   +6 more
doaj   +1 more source

A Hepatocyte‐to‐Stellate Cell Axis Couples Alternate‐Day Fasting to Liver Fibrosis Resolution via ATG7 S‐Nitrosylation

Advanced Science, EarlyView.
Alternate‐day fasting suppresses mitochondrial complex II assembly via SDHAF4 to upregulate hepatocyte eNOS. The resulting nitric oxide S‐nitrosylates ATG7 at C184 in hepatic stellate cells, restraining autophagic flux and preventing their profibrotic activation.
Xueqiang Wang, Mengqi Zeng, Cunxiao Sun, Yuhan Gou, Zhaode Feng, Weiqiang Lv, Chaoying Yan, Hansen Wu, Pengfei Zhang, Jie Xu, Ke Cao, Hao Li, Mingge Ding, Zhongbo Liu, Xing Zhang, Jiankang Liu, Xuan Zou, Zhihui Feng   +17 more
wiley   +1 more source

Effects of Once-Weekly Semaglutide on Cardiovascular Risk Factors and Metabolic Dysfunction-Associated Steatotic Liver Disease in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study Based on Real-World Data

Biomedicines
Once-weekly semaglutide is a widely used glucagon-like peptide-1 receptor agonist (GLP-1RA) used for the treatment of type 2 diabetes (T2D). In clinical trials, semaglutide improved glycemic control and obesity, and reduced major cardiovascular events ...
Hisayuki Katsuyama, Mariko Hakoshima, Emika Kaji, Masaaki Mino, Eiji Kakazu, Sakura Iida, Hiroki Adachi, Tatsuya Kanto, Hidekatsu Yanai   +8 more
doaj   +1 more source

Ciliary Membrane Lipid Homeostasis in Health and Disease

Advanced Science, EarlyView.
This review systematically delineates the distinct lipid landscapes of ciliary membranes, including the spatial organization of phosphoinositides, cholesterol, and sphingolipids. It elucidates how these lipids orchestrate ciliogenesis, signal transduction, and membrane dynamics in cilia beating, and highlights how their dysregulation drives ...
Zhenzhou Huang, Yuan‐yuan Liu, Hanqi Sun, Peiwei Liu   +3 more
wiley   +1 more source

Potentiation of the restorative effect of semaglutide on metabolic and hormonal parameters in rats with diet-induced type 2 diabetes mellitus with intranasally administered insulin

Сибирский научный медицинский журнал
Semaglutide, a glucagon-like peptide-1 receptor agonist, is widely used for the treatment of type 2 diabetes mellitus (DM2), but it is not effective in some patients, which requires the development of approaches to enhance its therapeutic effect.
K. V. Derkach, N. E. Basova, A. O. Shpakov   +2 more
doaj   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Impact of semaglutide on osteoarthritis risk in patients with obesity: A retrospective cohort study

Obesity Science & Practice
Background Osteoarthritis (OA) is a prevalent degenerative joint disorder. While the effect of obesity on OA is well documented, less is known about the effect of semaglutide on OA.
Onur Baser, Lauren Isenman, Sefika Baser, Gabriela Samayoa   +3 more
doaj   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source